Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
- Conditions
- NarcolepsySleep Apnea, ObstructiveSleep Apnea SyndromesShift-Work Sleep Disorder
- Registration Number
- NCT00078312
- Lead Sponsor
- Cephalon
- Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure \[nCPAP\] therapy), or chronic shift work sleep disorder (SWSD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 328
Patients are included in the study if all of the following criteria are met:
-
Written informed consent is obtained.
-
Men and women (outpatients) of any ethnic origin, between 18 and 65 years of age (inclusive) are eligible.
-
The patient has a complaint of excessive sleepiness associated with a current diagnosis of:
-
Narcolepsy-Diagnosis made on the basis of International Classification of Sleep Disorders (ICSD) (American Sleep Disorders Association 2000) criteria.
-
OSAHS-Diagnosis made on the basis of ICSD criteria. Furthermore, patients with OSAHS must meet the following nCPAP therapy requirements:
- Previous adequate education and intervention efforts to encourage nCPAP therapy use must be documented.
- A patient's nCPAP therapy regimen must be stable for at least 4 weeks.
- nCPAP therapy is effective, in the opinion of the investigator.
- Evidence of regular nCPAP usage must be shown during a 2 week evaluation period (ie, nCPAP therapy usage of at least 4 hours/night on at least 70% of the nights).
-
Chronic SWSD-Diagnosis made on the basis of at least minimum ICSD criteria. Furthermore, patients with chronic SWSD must have had excessive sleepiness during night shifts for at least 3 months, work a minimum of 3 night shifts per month that include at least 6 hours between 2200 and 0800 and are no longer than 12 hours in duration, and plan to continue to work night shifts throughout the study.
-
-
The patient has a Clinical Global Impression of Severity of Disease (CGI-S) rating of 4 or more. (For patients with OSAHS, the CGI-S scale will be administered after nCPAP effectiveness and regular usage is established. For patients with narcolepsy or OSAHS, CGI-S will be evaluated to assess general clinical condition. For patients with SWSD, CGI-S will be evaluated to assess sleepiness during the night shift including the commute to and from work.)
-
The patient is in good health as determined by a medical and psychiatric history, medical examination, electrocardiogram (ECG), serum chemistry and hematology. Women must be surgically sterile, 2 years postmenopausal, or if of childbearing potential, must use a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]).
-
The patient may have been prescribed PROVIGIL or stimulant therapy to treat the sleep disorder; however, they must have undergone a washout period of at least 7 days prior to screening assessments.
-
The patient must be willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.
Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- have any clinically significant, uncontrolled medical conditions (treated or untreated)
- have a probable diagnosis of a current sleep disorder other than the primary diagnosis of narcolepsy, OSAHS, or chronic SWSD
- consume caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine or more than 8 cups of coffee per day
- used any prescription drugs disallowed by the protocol or clinically significant use of over-the-counter (OTC) drugs within 7 days before the baseline visit
- have a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM IV)
- have a positive UDS at the screening visit
- have a clinically significant deviation from normal in the physical examination
- are pregnant or lactating. Any woman becoming pregnant during the study will be withdrawn from the study
- have used an investigational drug within 1 month before the screening visit
- have any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)
- have a known clinically significant drug sensitivity to stimulants
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety and Tolerability as Measured by Number of Participants With Adverse Events Screening/Baseline and months 1, 3, 6, 9, and 12 and every 3 months thereafter Serious and Non-serious Adverse Events (SAEs). Serious adverse event is any adverse event occurring at any dose that results in any of the following outcomes: death, life-threatening, inpatient hospitalization, persistent or significant disability, congenital anomaly, or an important medical event. An adverse event that does not meet any of the criteria for seriousness listed previously will be regarded as a nonserious adverse event.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (50)
Bay Area Research Institute
🇺🇸Lafayette, California, United States
Clinical Research Group of St. Petersburg
🇺🇸St. Petersburg, Florida, United States
Radiant Research, Boise
🇺🇸Boise, Idaho, United States
Vince and Associates Clinical Research
🇺🇸Overland Park, Kansas, United States
North Shore University Hospital
🇺🇸Manhasset, New York, United States
Radiant Research, Chicago
🇺🇸Chicago, Illinois, United States
Herron Medical Center, Ltd.
🇺🇸Chicago, Illinois, United States
Synergy Clinical Research Center
🇺🇸San Diego, California, United States
BMR HealthQuest Clinical Trials
🇺🇸San Diego, California, United States
Clinical Research Center of Nevada
🇺🇸Las Vegas, Nevada, United States
Arkansas Center for Sleep Medicine
🇺🇸Little Rock, Arkansas, United States
City Clinical Hospital No. 81
🇷🇺Moscow, Russian Federation
NeuroTrials Research of New Orleans, LLC
🇺🇸Metairie, Louisiana, United States
Institute of Pulmonology
🇷🇺Moscow, Russian Federation
Moscow City Somnological Center
🇷🇺Moscow, Russian Federation
Cardioclinic
🇷🇺Saint Petersburg, Russian Federation
IPS Research Company
🇺🇸Oklahoma City, Oklahoma, United States
Clinical Research Studies
🇺🇸Oklahoma City, Oklahoma, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Radiant Research, San Antonio
🇺🇸San Antonio, Texas, United States
Central Phoenix Medical Clinic, LLC
🇺🇸Phoenix, Arizona, United States
Anderson Clinical Research
🇺🇸Redlands, California, United States
Radiant Research - Tucson
🇺🇸Tucson, Arizona, United States
Pivotal Research Centers
🇺🇸Peoria, Arizona, United States
Central Arkansas Research
🇺🇸Hot Springs, Arkansas, United States
Neuro-Therapeutics Inc.
🇺🇸Pasadena, California, United States
Pharmacology Research Institute
🇺🇸Los Alamitos, California, United States
Rocky Mountain Center for Clinical Research
🇺🇸Wheat Ridge, Colorado, United States
Precision Research
🇺🇸Hallandale, Florida, United States
Therafirst Medical Centers
🇺🇸Ft. Lauderdale, Florida, United States
Radiant Research Alexian Brothers
🇺🇸Elk Grove Village, Illinois, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Henry W. Lahmeyer, MD and Associates
🇺🇸Northfield, Illinois, United States
Michigan Head-Pain Neurological Institute
🇺🇸Ann Arbor, Michigan, United States
Marc Raphaelson, MD, PA
🇺🇸Frederick, Maryland, United States
Somnos Laboratories, Inc
🇺🇸Lincoln, Nebraska, United States
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
Long Island Clinical Research Associates, LLP
🇺🇸Great Neck, New York, United States
CNS Research Institute, PC
🇺🇸Clementon, New Jersey, United States
North Coast Clinical Trials, Inc
🇺🇸Beachwood, Ohio, United States
Lehigh Valley Hospital Hospital
🇺🇸Allentown, Pennsylvania, United States
SleepMed of South Carolina
🇺🇸Columbia, South Carolina, United States
Center for Sleep Disorders, Inc.
🇺🇸Pottstown, Pennsylvania, United States
Northwest Clinical Research Center
🇺🇸Bellevue, Washington, United States
City Clinical Hospital No. 83
🇷🇺Moscow, Russian Federation
United Hospital and Out-patient Clinic of Presidential Medical Center of Russian Federation
🇷🇺Moscow, Russian Federation
Center of Rehabilitation of Presidential Medical Center
🇷🇺Moscow, Russian Federation
Clinic of Neurology and Neurosurgery of Saint Petersburg
🇷🇺Saint Petersburg, Russian Federation
Medical Sanitary Unit No. 122 of Saint-Petersburg
🇷🇺Saint-Petersburg, Russian Federation
Radiant Research
🇺🇸Salt Lake City, Utah, United States